These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 15315839)

  • 21. AIM2 co-immunization favors specific multifunctional CD8(+) T cell induction and ameliorates coxsackievirus B3-induced chronic myocarditis.
    Chai D; Yue Y; Xu W; Dong C; Xiong S
    Antiviral Res; 2015 Jul; 119():68-77. PubMed ID: 25956163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AIM2 Co-immunization with VP1 Is Associated with Increased Memory CD8 T Cells and Mounts Long Lasting Protection against Coxsackievirus B3 Challenge.
    Yin L; Chai D; Yue Y; Dong C; Xiong S
    Front Cell Infect Microbiol; 2017; 7():247. PubMed ID: 28642849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel bi-functional DNA vaccine expressing VP1 protein and producing antisense RNA targeted to 5'UTR of foot-and-mouth disease virus can induce both rapid inhibitory effect and specific immune response in mice.
    Yang B; Lan X; Li X; Yin X; Li B; Han X; Li Y; Zhang Z; Liu J
    Vaccine; 2008 Oct; 26(43):5477-83. PubMed ID: 18694793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co-expression of interleukin-2 to increase the efficacy of DNA vaccine-mediated protection in coxsackievirus B3-infected mice.
    Henke A; Chiang CS; Zell R; Stelzner A
    Antiviral Res; 2004 Nov; 64(2):131-6. PubMed ID: 15498609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of immunogenicity and immunoprotection of mucosal vaccine against coxsackievirus B3 by optimizing the coadministration mode of lymphotactin adjuvant.
    Yue Y; Xu W; Xiong S
    DNA Cell Biol; 2012 Apr; 31(4):479-88. PubMed ID: 21988406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B.
    Khatri K; Goyal AK; Gupta PN; Mishra N; Vyas SP
    Int J Pharm; 2008 Apr; 354(1-2):235-41. PubMed ID: 18182259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The viral genetic background determines the outcome of coxsackievirus B3 infection in outbred NMRI mice.
    Schmidtke M; Merkle I; Klingel K; Hammerschmidt E; Zautner AE; Wutzler P
    J Med Virol; 2007 Sep; 79(9):1334-42. PubMed ID: 17607777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Experimental study on the chitosan-DNA vaccines against campylobacter jejuni invasion].
    Zheng H; Cai FC; Zhong M; Deng B; Li X; Zhang XP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2007 Sep; 41(5):375-9. PubMed ID: 18206008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An intranasal attenuated Coxsackievirus B3 vaccine induces strong systemic and mucosal immunity against CVB3 lethal challenge.
    Deng H; Li Y; He X; Wang H; Wang S; Zhang H; Zhu J; Gu L; Li R; Wang G
    J Med Virol; 2024 Aug; 96(8):e29831. PubMed ID: 39072815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection.
    Chen HL; Huang JY; Chu TW; Tsai TC; Hung CM; Lin CC; Liu FC; Wang LC; Chen YJ; Lin MF; Chen CM
    Vaccine; 2008 Jun; 26(23):2882-9. PubMed ID: 18450335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization.
    Hotomi M; Ikeda Y; Suzumoto M; Yamauchi K; Green BA; Zlotnick G; Billal DS; Shimada J; Fujihara K; Yamanaka N
    Vaccine; 2005 Jan; 23(10):1294-300. PubMed ID: 15652672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA vaccination against foot-and-mouth disease via electroporation: study of molecular approaches for enhancing VP1 antigenicity.
    Kim SA; Liang CM; Cheng IC; Cheng YC; Chiao MT; Tseng CJ; Lee F; Jong MH; Tao MH; Yang NS; Liang SM
    J Gene Med; 2006 Sep; 8(9):1182-91. PubMed ID: 16927362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune responses generated by Lactobacillus as a carrier in DNA immunization against foot-and-mouth disease virus.
    Li YG; Tian FL; Gao FS; Tang XS; Xia C
    Vaccine; 2007 Jan; 25(5):902-11. PubMed ID: 17028078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal administration of a recombinant adenovirus expressing the norovirus capsid protein stimulates specific humoral, mucosal, and cellular immune responses in mice.
    Guo L; Wang J; Zhou H; Si H; Wang M; Song J; Han B; Shu Y; Ren L; Qu J; Hung T
    Vaccine; 2008 Jan; 26(4):460-8. PubMed ID: 18160189
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
    Patel GB; Zhou H; Ponce A; Chen W
    Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spontaneous C-cleavage of a truncated intein as fusion tag to produce tag-free VP1 inclusion body nanoparticle vaccine against CVB3-induced viral myocarditis by the oral route.
    Qi X; Lu Q; Hu J; Xiong S
    Microb Cell Fact; 2019 Apr; 18(1):66. PubMed ID: 30947747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective immunity induced by systemic and mucosal delivery of DNA vaccine expressing glycoprotein B of pseudorabies virus.
    Yoon HA; Han YW; Aleyas AG; George JA; Kim SJ; Kim HK; Song HJ; Cho JG; Eo SK
    J Microbiol Biotechnol; 2008 Mar; 18(3):591-9. PubMed ID: 18388482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protection of mice against lethal coxsackievirus B3 infection by using DNA immunization.
    Henke A; Wagner E; Whitton JL; Zell R; Stelzner A
    J Virol; 1998 Oct; 72(10):8327-31. PubMed ID: 9733878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease.
    Henke A; Jarasch N; Martin U; Wegert J; Wildner A; Zell R; Wutzler P
    Int J Med Microbiol; 2008 Jan; 298(1-2):127-34. PubMed ID: 17897883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.